C5 and paroxysmal nocturnal hemoglobinuria: Phase 2 studies assessing its efficacy and safety in PNH have been conducted and an extension study is ongoing.82 Coversin is a broad-acting C5 inhibitory protein that successfully reduced LDH levels to < 1.8 × ULN in untreated patients using an SC self-administered formulation.81 Cemdisiran is an RNA interference therapeutic that targets hepatic C5 synthesis and has been shown to reduce levels of C5 in patients with PNH.78